Which Labs Are Needed Before My First Appointment? | Calibrate

Why Pre-Appointment Labs Matter for GLP-1 and Metabolic Therapy

Getting labs before your first visit is not a bureaucratic hurdle. Your physician needs objective metabolic data to prescribe safely and to give you a measurable starting point. GLP-1 receptor agonists such as semaglutide and tirzepatide have specific contraindications, including a personal or family history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia type 2 (MEN2), and baseline labs help rule out related endocrine abnormalities before a prescription is written [1].

What Happens Without Baseline Labs

A prescriber working without labs is essentially flying blind. Undiagnosed hypothyroidism, for example, can cause weight gain that mimics simple obesity and can blunt the response to GLP-1 therapy if left untreated [2]. Undetected prediabetes changes the clinical picture entirely, because a patient with an HbA1c of 6.2% may qualify for different GLP-1 agents and dosing protocols than someone with a normal HbA1c of 5.1%.

The Regulatory and Safety Framework

The FDA label for semaglutide 2.4 mg (Wegovy) requires prescribers to evaluate patients for contraindications before initiating therapy, and the American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommend routine metabolic labs as part of the pre-treatment evaluation [3]. Telehealth platforms operating under that framework, including Calibrate, follow the same clinical standard.

The Complete Required Lab Panel

1. Thyroid-Stimulating Hormone (TSH)

TSH is the single most informative first-line thyroid test. The pituitary releases TSH to signal the thyroid gland to produce more hormone. When thyroid function is low (hypothyroidism), TSH rises; when the thyroid is overactive (hyperthyroidism), TSH falls [4].

The standard reference range used by most U.S. Laboratories is approximately 0.4 to 4.0 mIU/L, though some endocrinology groups argue the upper limit should be closer to 2.5 mIU/L for certain populations [5]. A TSH outside the normal range before starting a GLP-1 program indicates that thyroid function should be optimized first or managed concurrently, because uncontrolled hypothyroidism independently raises cardiovascular risk and impairs weight loss.

Why it matters for GLP-1 candidacy: GLP-1 receptor agonists carry an FDA boxed warning for the risk of thyroid C-cell tumors observed in rodent studies. While the clinical significance in humans remains under study, prescribers are required to take a thyroid history and may order additional thyroid imaging or calcitonin testing if TSH results are abnormal [1].

2. Hemoglobin A1c (HbA1c)

HbA1c reflects average blood glucose over the prior 8-12 weeks. The American Diabetes Association classifies results as follows: below 5.7% is normal, 5.7-6.4% is prediabetes, and 6.5% or above on two separate tests confirms diabetes [6].

This single number dramatically affects the treatment plan. In the STEP-1 trial (N=1,961), participants without diabetes achieved 14.9% mean body weight loss at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo [7]. Participants with type 2 diabetes in the STEP-2 trial (N=1,210) achieved 9.6% weight loss versus 3.4% on placebo, with simultaneous HbA1c reductions of 1.6 percentage points [8]. Knowing your HbA1c before the appointment tells your physician exactly where you sit on that clinical spectrum.

3. Fasting Lipid Panel

A fasting lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides after a 9-12 hour fast. Dyslipidemia (abnormal cholesterol levels) affects roughly 38% of U.S. Adults according to CDC surveillance data [9], and it is one of the most common comorbidities in patients seeking metabolic therapy.

Clinical relevance: Elevated triglycerides above 500 mg/dL raise the risk of pancreatitis, which is itself a contraindication to some GLP-1 agents. Knowing lipid levels before prescribing allows the physician to assess that risk and to establish a cardiovascular risk profile that will be tracked over time as GLP-1 therapy improves lipid parameters.

4. Comprehensive Metabolic Panel (CMP)

The CMP is a 14-test blood panel that evaluates kidney function (creatinine, blood urea nitrogen), liver function (ALT, AST, alkaline phosphatase, bilirubin), electrolytes (sodium, potassium, chloride, bicarbonate), and fasting glucose [10].

Each of these components informs prescribing decisions:

• Liver enzymes (ALT/AST): GLP-1 therapy has shown benefit in metabolic-associated steatotic liver disease (MASLD, formerly NAFLD), but baseline values are needed to monitor that effect. In the LEAN trial, liraglutide 1.8 mg resolved NASH histologically in 39% of participants versus 9% on placebo [11].
• Kidney function (eGFR/creatinine): Semaglutide is generally safe in mild-to-moderate chronic kidney disease, but dosing and monitoring differ in more advanced renal impairment.
• Fasting glucose: A stand-alone data point that cross-validates the HbA1c result.

5. Complete Blood Count (CBC)

The CBC measures red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. It screens for anemia, infection, and clotting abnormalities that could affect your overall health status and the safety of starting a new therapeutic regimen.

Iron-deficiency anemia, the most common nutritional deficiency worldwide affecting approximately 1.2 billion people globally [12], can cause fatigue that overlaps with hypothyroid symptoms and may affect how a patient tolerates the early phase of a low-calorie dietary program.

Additional Labs That May Be Ordered

Not every patient needs every test. Your Calibrate physician may add the following based on your intake questionnaire responses, personal history, or abnormal results in the core panel.

Amylase and Lipase

If you report a history of pancreatitis, gallbladder disease, or heavy alcohol use, your physician may order amylase and lipase. Elevated lipase above three times the upper limit of normal is a clinical marker for acute pancreatitis. GLP-1 receptor agonists are generally contraindicated in patients with a prior history of pancreatitis [1].

Calcitonin

Calcitonin is produced by thyroid C-cells. Elevated calcitonin can be a marker for medullary thyroid carcinoma. Because GLP-1 receptor agonist labels carry a boxed warning related to MTC risk (based on rodent data), prescribers may order serum calcitonin in patients who report a family history of MTC or MEN2, or when TSH results are atypical [1][13].

The American Thyroid Association notes that routine calcitonin screening in all patients before GLP-1 therapy is not yet standard practice in the U.S., though it is more widely used in some European clinical settings [13].

Free T4 and Free T3

If TSH is abnormal, free thyroxine (free T4) and free triiodothyronine (free T3) are the natural follow-up tests. Free T4 reflects the primary hormone the thyroid secretes. Free T3 is the active form at the cellular level. A low TSH combined with a high free T4 confirms hyperthyroidism; a high TSH with a low free T4 confirms primary hypothyroidism [4][5].

Fasting Insulin and HOMA-IR

Some metabolic programs include fasting insulin to calculate the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). HOMA-IR = (fasting insulin in µU/mL × fasting glucose in mmol/L) / 22.5. A HOMA-IR above 2.0 suggests insulin resistance, and values above 2.9 are associated with metabolic syndrome in population studies [14]. This result can guide how aggressively dietary changes are introduced alongside GLP-1 initiation.

hsCRP (High-Sensitivity C-Reactive Protein)

Chronic low-grade inflammation is a hallmark of obesity-related metabolic dysfunction. An hsCRP above 3.0 mg/L places a patient in the high cardiovascular risk category according to the American Heart Association [15]. GLP-1 therapy has been shown to reduce hsCRP, making the baseline value useful for tracking anti-inflammatory response over time.

How to Get Your Labs Before the Appointment

Using the Calibrate Lab Order

Calibrate sends a digital lab order to Quest Diagnostics in most states after you complete your intake forms. You schedule your own Quest appointment online at no additional scheduling fee. Results are uploaded directly to your Calibrate account, and your physician reviews them before the video visit. This typically takes 1-3 business days from the blood draw.

Using Your Own Doctor's Lab Order or Insurance

If you have a primary care physician, you may request the same panel through your own provider. Most private insurance plans cover annual preventive labs including a CMP, CBC, and lipid panel under the Affordable Care Act's preventive care mandate with no cost-sharing when ordered as part of a wellness visit [16]. HbA1c and TSH may be covered as diagnostic tests depending on your plan and whether a diagnosis code (such as obesity, ICD-10 E66, or prediabetes screening) is applied.

Walk-In Options at LabCorp or Quest

Both Quest Diagnostics and LabCorp offer walk-in and scheduled appointments at over 8,000 combined patient service centers across the U.S. Without insurance, a standard metabolic panel including CMP, CBC, HbA1c, TSH, and lipid panel costs roughly $100-$300 depending on your location and which bundled pricing options you select.

What Fasting Requirements Apply

Fasting for 9-12 hours before your blood draw is necessary for two specific components: the fasting glucose (part of the CMP) and the fasting lipid panel. Non-fasting triglyceride measurements are unreliable and can produce falsely elevated readings that might incorrectly suggest pancreatitis risk.

TSH, HbA1c, and CBC do not require fasting. Water is always permitted. Black coffee without cream or sugar has a minimal effect on most metabolic markers but is generally discouraged for strict standardization in clinical practice.

Schedule your draw in the morning. This minimizes the fasting window and reduces the chance of hypoglycemia symptoms in patients who are already managing blood sugar. Most Quest and LabCorp locations open at 7:00 or 7:30 a.m.

How Results Are Interpreted Before Your Visit

Your Calibrate physician reviews results against standard reference ranges and your individual intake information. Here is what abnormal results typically trigger:

| Result | Threshold | Likely Next Step | |--------|-----------|-----------------| | TSH above 10 mIU/L | Overt hypothyroidism | Thyroid treatment before or concurrent with GLP-1 start | | HbA1c 6.5% or above | Diabetes confirmed | Semaglutide (Ozempic) preferred; Wegovy label requires diabetes management plan | | Triglycerides above 500 mg/dL | Pancreatitis risk | GLP-1 may be deferred; fibrate therapy discussion | | ALT/AST above 3x upper limit | Hepatocellular injury | Further workup before initiating therapy | | eGFR <30 mL/min/1.73m² | Severe CKD | Dose adjustment and nephrology coordination | | Calcitonin above 100 pg/mL | MTC concern | Endocrinology referral; GLP-1 contraindicated |

The physician may clear you to start immediately, recommend a short delay to address an abnormal finding, or refer you to a specialist. Most patients with a normal or mildly abnormal panel receive their prescription within days of the lab visit.

What to Do After Your Labs Are Reviewed

Once your results are in and your physician has reviewed them, your first video appointment focuses on your weight history, metabolic goals, dietary preferences, and the specifics of your GLP-1 titration schedule. The American Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends initiating GLP-1 therapy at the lowest available dose and titrating every 4 weeks based on tolerance, with metabolic labs repeated at 3 months after initiation [17].

Keep a copy of your baseline labs. Comparing your 3-month results to your baseline is one of the most motivating early milestones. Patients who saw their HbA1c drop from prediabetic to normal range, or their triglycerides fall by 30-40%, often describe that numerical feedback as a turning point in their commitment to the program.

Monitoring Labs After You Start

Pre-appointment labs are only the first set. After starting GLP-1 therapy, most Calibrate physicians reorder a CMP and lipid panel at 3 months to assess liver enzyme trends, kidney function, and lipid response. HbA1c is repeated at 3-6 months depending on baseline values. TSH is typically rechecked at 6-12 months unless symptoms of thyroid dysfunction arise sooner.

In the SELECT cardiovascular outcomes trial (N=17,604), semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo over a mean follow-up of 34.2 months in patients with pre-existing cardiovascular disease and BMI of 27 or above [18]. Tracking lipids and inflammatory markers over time documents whether your individual response mirrors that population-level benefit.